Abstract 201P
Background
Hepatocellular carcinoma (HCC) accounts for around 90% of liver cancer cases, and there are still significant therapeutic challenges. This study aimed to assess the safety and preliminary efficacy of serplulimab, a novel programmed cell death-1 inhibitor, with or without the bevacizumab biosimilar HLX04 in patients with advanced HCC.
Methods
Patients with advanced HCC who failed prior systemic therapy received serplulimab 3 mg/kg plus HLX04 5 mg/kg (group A), serplulimab 3 mg/kg plus HLX04 10 mg/kg (group B), or serplulimab 3 mg/kg monotherapy (group C). Patients with previously untreated advanced HCC were enrolled in group D and given serplulimab 3 mg/kg plus HLX04 10 mg/kg. All treatments were administered intravenously every 2 weeks. The primary endpoint was safety.
Results
This open-label, multicentre phase 2 study was conducted in China; 28 hospitals enrolled patients. Results of group A and B have been previously published; here we present results of group C and D. As of 7 February 2023, 21 and 61 patients were enrolled in group C and D. The median follow-up duration was 26.0 and 25.5 months, respectively. 10 (47.6%) patients in group C and 29 (47.5%) in group D reported grade ≥3 treatment-emergent adverse events. 1 (4.8%) patient in group C died from treatment-related hepatic failure; 1 (1.6%) in group D died from treatment-related hepatic failure and disease progression. As assessed by an independent radiological review committee (IRRC) per RECIST v1.1, the objective response rate was 4.8% (95% confidence interval [CI] 0.1–23.8) in group C and 27.9% (95% CI 17.1–40.8) in group D. IRRC-assessed median progression-free survival was 1.8 months (95% CI 1.4–2.8) and 7.3 months (95% CI 2.8–11.0) in group C and D, respectively. Median overall survival was 16.0 months (95% CI 3.6–not evaluable [NE]) in group C and 19.1 months (95% CI 14.3–NE) in group D.
Conclusions
In the first-line and subsequent-line settings, serplulimab plus HLX04 and serplulimab monotherapy, respectively, showed a manageable safety profile together with encouraging efficacy in patients with advanced HCC.
Clinical trial identification
NCT03973112 (released on 4 June 2019).
Editorial acknowledgement
Editorial assistance was provided by Shiqi Zhong, Zhi Hao Kwok, and Chen Hu of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
X. Hou, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract